Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 29.1
(0.0%)
TWD 29.1
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 296.37 Million | 425.29 Million | 135.54 Million | 146.39 Million | -79.48 Million | 79.5 Million |
| Net Income | 305.7 Million | 245.04 Million | -184.52 Million | -117.77 Million | -86.7 Million | -87.68 Million |
| Depreciation & Amortization | 243.52 Million | 266.71 Million | 269.37 Million | 250.42 Million | 236.76 Million | 238.8 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -131.72 Million | -40.78 Million | 91.07 Million | 87.26 Million | -186.96 Million | -25.08 Million |
| Other non-cash items | -121.13 Million | -45.67 Million | -40.37 Million | -73.51 Million | -42.58 Million | -46.53 Million |
| Investing Cash Flow | -334.56 Million | -124.23 Million | -205.59 Million | -165.68 Million | -210.84 Million | -179.41 Million |
| Investments in PPE | -300.93 Million | -153.44 Million | -161.44 Million | -157.77 Million | -176.73 Million | -255.69 Million |
| Acquisitions | -7.92 Million | -8.55 Million | -14.72 Million | -13.26 Million | -5.17 Million | 6.67 Million |
| Investment purchases | -2.45 Million | -9.67 Million | -43.44 Million | -212.69 Million | -122.36 Million | -153.35 Million |
| Sales/Maturities of investments | 7.92 Million | 43.44 Million | 43.77 Million | 207.66 Million | 93.57 Million | 231.04 Million |
| Other Investing Activities | -31.17 Million | 3.99 Million | -29.75 Million | 10.38 Million | -145 Thousand | -8.08 Million |
| Financing Cash Flow | -106.84 Million | -263.32 Million | 122.95 Million | 318.72 Million | 182.21 Million | -8.28 Million |
| Debt repayment | -31.5 Million | -399.06 Million | -103.91 Million | -145.73 Million | -28.3 Million | -62.81 Million |
| Dividends payments | -167.72 Million | -33.54 Million | -33.54 Million | -33.54 Million | -16.77 Million | -33.54 Million |
| Common Stock Repurchased | - | - | 85 Million | - | - | - |
| Common Stock Issuance | 30.04 Million | - | 15.58 Million | 7.9 Million | 18.13 Million | 40.72 Million |
| Other Financing Activities | -666 Thousand | 169.28 Million | 159.83 Million | 206.54 Million | 170.68 Million | -37.54 Million |
| Accounts receivables | 40.05 Million | -92.72 Million | -140.88 Million | 167.64 Million | -64.45 Million | -47.81 Million |
| Accounts payables | -31.97 Million | 121.92 Million | 7.04 Million | -15.78 Million | 27.69 Million | 27.02 Million |
| Inventory | -102.18 Million | -39.62 Million | -15.94 Million | -114.44 Million | -78.94 Million | 34.37 Million |
| Other working capital | -37.62 Million | -30.35 Million | 240.86 Million | 49.84 Million | -71.26 Million | -59.45 Million |
| Cash at beginning of period | 1.23 Billion | 1.19 Billion | 1.14 Billion | 840.71 Million | 958.52 Million | 1.07 Billion |
| Cash at end of period | 1.07 Billion | 1.23 Billion | 1.19 Billion | 1.14 Billion | 840.71 Million | 958.52 Million |
| Capital Expenditure | -300.93 Million | -153.44 Million | -161.44 Million | -157.77 Million | -176.73 Million | -255.69 Million |
| Effect of forex changes on cash | -4.2 Million | 5.03 Million | -1.88 Million | 3.61 Million | -9.68 Million | -3.47 Million |
| Net cash flow / Change in cash | -163.06 Million | 42.77 Million | 51.01 Million | 303.05 Million | -117.8 Million | -111.66 Million |
| Free Cash Flow | -4.56 Million | 271.85 Million | -25.9 Million | -11.37 Million | -256.22 Million | -176.19 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 64.93 Million | 78.98 Million | 305.7 Million | 110.32 Million | 63.94 Million | 37.89 Million |
| Depreciation & Amortization | 63.11 Million | 63.45 Million | 243.52 Million | 64.32 Million | 60.56 Million | 59.08 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 4.26 Million | -80.84 Million | -131.72 Million | 27.55 Million | -58.11 Million | 116.63 Million |
| Other non-cash items | 155.81 Million | 6.2 Million | -121.13 Million | -61.39 Million | -9.47 Million | -47.76 Million |
| Investing Cash Flow | -104.59 Million | -104.56 Million | -334.56 Million | -84.54 Million | -123.19 Million | -79.74 Million |
| Investments in PPE | -64.69 Million | -100.41 Million | -300.93 Million | -82.93 Million | -98.24 Million | -73.86 Million |
| Acquisitions | 161 Thousand | - | -7.92 Million | 152 Thousand | -9.18 Million | 554 Thousand |
| Investment purchases | -44.44 Million | -5.14 Million | -2.45 Million | - | - | -2.45 Million |
| Sales/Maturities of investments | - | - | 7.92 Million | - | - | 1.89 Million |
| Other Investing Activities | 4.38 Million | 984 Thousand | -31.17 Million | -1.75 Million | -15.76 Million | -5.87 Million |
| Financing Cash Flow | -10.98 Million | -12.63 Million | -106.84 Million | 28.69 Million | 46.14 Million | -18.82 Million |
| Debt repayment | -11.98 Million | -12.63 Million | -31.5 Million | -1.3 Million | -214.48 Million | -18.82 Million |
| Dividends payments | - | - | -167.72 Million | - | -167.72 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 30.04 Million | 30.04 Million | - | - |
| Other Financing Activities | 1 Million | 1000.00 | -666 Thousand | -46 Thousand | -614 Thousand | -6000.00 |
| Accounts receivables | -23.82 Million | -39.58 Million | 40.05 Million | 6.12 Million | -46.27 Million | 69.01 Million |
| Accounts payables | -9.32 Million | 9.61 Million | -31.97 Million | 13.36 Million | 2.64 Million | -14.38 Million |
| Inventory | 17.52 Million | -16 Thousand | -102.18 Million | -22.21 Million | -28.41 Million | 10.39 Million |
| Other working capital | 19.89 Million | -50.8 Million | -37.62 Million | 30.27 Million | 13.93 Million | 51.61 Million |
| Cash at beginning of period | 1.02 Billion | 1.07 Billion | 1.23 Billion | 995.13 Million | 1.01 Billion | 962.47 Million |
| Cash at end of period | 1.05 Billion | 1.02 Billion | 1.07 Billion | 1.07 Billion | 995.13 Million | 1.01 Billion |
| Capital Expenditure | -64.69 Million | -100.41 Million | -300.93 Million | -82.93 Million | -98.24 Million | -73.86 Million |
| Effect of forex changes on cash | 2.41 Million | 5.22 Million | -4.2 Million | -5.53 Million | 11.05 Million | -11.46 Million |
| Net cash flow / Change in cash | 33.12 Million | -52.7 Million | -163.06 Million | 79.35 Million | -22.32 Million | 54.98 Million |
| Free Cash Flow | 81.58 Million | -41.14 Million | -4.56 Million | 57.86 Million | -41.31 Million | 91.97 Million |
GTK
9917
TPP
3042
8200
3680